Selected Publications

Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM. : Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Eur Heart J Open 3(6), November 2023.

Chukwurah MI, Miller M: Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering? Curr Cardiol Rep 2023.

Miller M: REDUCE-IT: Findings and Implications for Practice. Br J Cardiol 2023.

Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif JC, Ballantyne CM, Chung MK; REDUCE‐IT Investigators. : Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. J Am Heart Assoc 2023.

Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Ballantyne CM, Budoff M, Mason RP; REDUCE-IT Investigators.: Potential Effects of Icosapent Ethyl on Cardiovascular Outcomes in Cigarette Smokers: REDUCE-IT Smoking. Eur Heart J Cardiovasc Pharmacother 2023.

Miller M on behalf of the authors Bhatt DL, Bays HE, Parli T, Feng S, Sterling L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP. : Phase 2 trial of pegozafermin in severe hypertriglyceridemia. Presented at the Annual National Lipid Association Scientific Sessions, Atlanta, GA 2023.

Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; : The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. ENTRIGUE Principal Investigators. Nat Med 2023.

Miller M, Bhatt DL, Brinton EA, et al.: Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in the Metabolic Syndrome:REDUCE-IT MetSyn. Circulation 2023.

Selvaraj S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Juliano RA, Jiao L, Tardif JC, Ballantyne CM; REDUCE‐IT Investigators.: Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc 2022.

Aggarwal M, Ros E, Allen K, Sikand G, Agarwala A, Aspry K, Kris-Etherton P, Devries S, Reddy K, Singh T, Litwin SE, Keefe JO, Miller M, Andrus B, Blankstein R, Batiste C, Belardo D, Wenger C, Batts T, Barnard ND, White BA, Ornish D, Williams KA, Ostfeld RJ, Freeman AM: Controversial Dietary Patterns: A High Yield Primer for Clinicians. Am J Med 2022.